Funder
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference47 articles.
1. Dohner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447
2. Wei AH, Tiong IS (2017) Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood 130(23):2469–2474
3. FDA (2017) Vyxeos (daunorubicin and cytarabine) liposome label. US Food and Drug Administration.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s209000lbl.pdf
. Accessed 23 Dec 2018
4. FDA (2017) Mylotarg (gemtuzumab ozogamicin) label. US Food and Drug Administration.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf
. Accessed 23 Dec 2018
5. FDA (2017) Rydapt (midostaurin) label. US Food and Drug Administration.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997Orig207991Orig207992s207000lbl.pdf
. Accessed 23 Dec 2018
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献